Fungi · Scientific monograph
Inonotus obliquus
Chaga
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Oxidative Stress Research, Immunological Research, Inflammatory Pathways
Research overview
Historical use
Used in folk medicine across Russia, Siberia, and Scandinavia (including Norway and Finland) since at least the 16th century. Traditionally prepared as a tea (decoction of the sclerotium) for GI diseases, tuberculosis, and cancer. Finnish records describe its use as a coffee substitute during WWII.
Modern research context
Studied primarily for antioxidant and anti-tumour activity [1][2]. Betulinic acid and polysaccharides show anti-proliferative effects in vitro and in animal models [2]. Anti-inflammatory and anti-hyperglycaemic effects have been observed in preclinical studies, including inhibition of intestinal inflammation and insulin metabolism impairment in Drosophila models [3]. Application in diabetic kidney disease is under investigation [4]. Human RCT data remains limited [1][5].
Adverse effects
Oxalate nephropathy with excessive long-term consumption (case reports documented). Potential hypoglycaemia. Rare hypersensitivity reactions. Theoretical bleeding risk.
Contraindications
Contraindicated in patients with chronic kidney disease or urolithiasis due to very high oxalate content. Avoid with anticoagulants and antidiabetic medications without monitoring. Avoid before surgery.
Clinical and phytochemical data
Used part
Sclerotium (sterile conk growing on birch trees)
Primary active compounds
Betulinic acid
Betulin
Inotodiol (lanostane triterpenoid)
Polysaccharides (beta-1,3-glucans)
Melanin-glucan complex
Ergosterol peroxide
Mechanism of action
Betulinic acid induces tumour cell apoptosis via the mitochondrial pathway (cytochrome c release, caspase-3 activation). Beta-glucans activate macrophages and NK cells via Dectin-1 and TLR-2/4 receptors. Melanin-glucan complex acts as a potent free-radical scavenger (DPPH, ABTS assays). Anti-inflammatory activity via inhibition of COX-2 and iNOS expression.
Pharmacokinetics
Absorption
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Betulinic acid has very poor oral bioavailability (<5%) due to low aqueous solubility. Polysaccharides have limited systemic absorption; exert local GI immunomodulatory effects.
Distribution
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Betulinic acid is highly lipophilic (logP ≈ 7.8) and distributes extensively into adipose tissue and the liver; plasma protein binding exceeds 99%. It does not readily penetrate the blood-brain barrier due to poor aqueous solubility. Polysaccharide fractions remain largely in the GI tract and GALT. No quantitative human tissue distribution data are available.
Metabolism
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Betulinic acid undergoes hepatic oxidative metabolism. Detailed human PK data not available.
Excretion
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Fecal excretion of unabsorbed polysaccharides and betulinic acid; oxalate excreted renally.
Safety and interactions
Drug interactions
Lack of clinical studies prevents interaction grading. Unknown safety profile with concomitant drug use.
Toxicity
LD50 data not established for whole extract in humans. High-dose aqueous extract associated with oxalate nephropathy (case reports: PMID 26392405). Renal accumulation of oxalate is the primary toxicity concern with chronic high-dose use.
Special precautions
Pregnancy
Insufficient safety data. Traditionally contraindicated. Avoid during pregnancy.
Lactation
No data on excretion in breast milk. Avoid during breastfeeding.
Hepatic impairment
No specific hepatotoxicity identified. Limited data; standard caution applies.
Renal impairment
Contraindicated or use with extreme caution due to high oxalate content — documented cases of oxalate nephropathy even in previously healthy individuals with excessive intake.
Sources and references
- [1] - Szychowski KA., "Inonotus obliquus - from folk medicine to clinical use.", J Tradit Complement Med, 2021, PMID: 34195023
- [2] - Tee PYE., "A review on the cultivation, bioactive compounds, health-promoting factors and clinical trials of medicinal mushrooms Taiwanofungus camphoratus, Inonotus obliquus and Tropicoporus linteus.", Fungal Biol Biotechnol, 2024, PMID: 38987829
- [3] - Yu S., "Inonotus obliquus aqueous extract inhibits intestinal inflammation and insulin metabolism defects in Drosophila.", Toxicol Mech Methods, 2024, PMID: 38872277
- [4] - Wang S., "Research Progress on Application of Inonotus obliquus in Diabetic Kidney Disease.", J Inflamm Res, 2023, PMID: 38161352
- [5] - Łysakowska P., "Medicinal Mushrooms: Their Bioactive Components, Nutritional Value and Application in Functional Food Production-A Review.", Molecules, 2023, PMID: 37513265